ARTICLE | Clinical News
Baxter Phase III hemophilia A data
May 21, 2002 7:00 AM UTC
BAX said preliminary data from a Phase III trial showed its recombinant antihemophilic Factor VIII prepared without the use of human- or animal-derived additives was bioequivalent to Recombinate recom...